Blog

In 2015, the Center for Disease Control (CDC) estimated that in the U.S., 1.2% of the population have active epilepsy (including 3 million adults and approximately 500,000 children).[1] Over 25 antiseizure medications (ASM) are currently approved by the United States Food and Drug Administration (FDA).[2] During a critical shortage of an ASM, the feasibility of a rapid transition to an alternate ASM is often difficult.[3] The FDA drug shortage database in July 2023 indicated a national shortage of ASMs often used in status epilepticus, including rectal diazepam, oral clonazepam, and intravenous preparations of lorazepam, midazolam, and valproic acid.